UBS Global Biopharma Conference - IMMUNOCORE HOLDINGS PLC
Hello, everyone. My name is Dina Almanchid, one of the biotech analysts here at UBS, and I am excited and pleased to welcome Travis Coy, Chief Financial Officer of Immunocore. I am excited for us to get started on this, and so maybe we can start with a couple of questions around the commercial business for ChemTrack. Maybe just, you know, we are probably in our fourth year of launch now, and so given, you know, pretty peak penetration levels in especially OUS market, and maybe 70% in the U.S., nearly there. So maybe just thinking about where are the remaining growth drivers, particularly in the community setting, both in the US and OUS, and where do you see ChemTrack from here in the outer years? Yeah, no, thanks, Dana. First of all, thank you for having me. Of course. And for having us. So a good question on ChemTracking. We're really pleased that ChemTracks has become the standard of care across all major markets. And you're elaborating to some of the penetration levels we have. We're at 70% plus penetration across all markets. And so as we look at the growth, naturally in this part of the product's life cycle, we're seeing growth begin to moderate. It's a good thing, right? We did a good job on launch, right. You launched very quickly. Yeah, we did. But as we looked, we still see opportunities for growth. And there's two different aspects. There's the U.S. and the O.U.S., from a U.U.'s perspective. our growth is centered and focused on penetrating further into that community setting, continue to increase patient access in that community settings. OUS, our growth mainly comes from new launches. We're 80% to 90% penetrated in some of those markets, so new launches are really where we see the growth, and again, it's increasing that patient access. We also see some growth OUS from increasing duration of therapy. So some of the markets where we've more recently launched, that duration of therapy is still ticking up to where it already is in established in established markets. Okay. That makes sense. Um, what is the duration of therapy now? I think the last time we've talked about this, maybe around 14 months. Um, um, what does it looking like now? And you know, nearly, you know 2027. Yeah. So, um and I'll, I'll mention we are five years on the market now, but that's okay. Um as we, so as we look at the duration of therapy in the U S it's mostly stabilized. Okay, I'd say it's fair to say across the major markets where we've been launched four or five years. We mostly see the duration of therapy around 14 months. What's remarkable about that is in the clinical setting, we saw around 10 to 11 months. And I think that's just a testament to the product's profile, right? And it's also what has been allowed us to be as successful as we have been pushing into the community setting. Because if physicians weren't comfortable with that product profile, weren't uncomfortable with, you know, um, patients getting benefit, then we wouldn't have, we wouldn'T have reached this duration of therapy that is incredibly rare to see in the real world longer than what we've seen in the clinical study. I actually want to point the next question about recent data that you presented at a medical conference just a couple of weeks ago. And that was also in uveal melanoma as well. Um, and that was looking at Kim track plus preem, if I remember that correctly. And And the data actually looked significantly better in a phase one study versus chemtrack monotherapy of what we have today on the market. I believe that you guys are moving that forward into potentially phase two, phase three. Maybe talk about how that is, you know, maybe not something that we're going to see to the long term or to the near term growth, but maybe a long term growth driver as we have, you know, better efficacious medicines with chemtrack and combinations that we can see on the market in UVL melanoma. Yeah. Yeah, so we're really excited by that data, and it was interesting. It's not just a testament to us. It's also a testament to investigators and KOLs that we're seeing the data and saying there's something going on here. And so just to re-summarize the data a little bit, you're exactly right. We saw and one thing that's important to note from a biology perspective is that PRAME is a negative prognostic in UVO melanoma, so there was very good biologic rationale for doing the combination to start with. But what we saw is from the very consistent clinical activity across all metrics, and I'll talk about those in a second, as well as no safety, additive safety, the safety profile of the combination was very consistent with the individual components. And so going back to the clinical activity a little bit, just to highlight some of the numbers we saw. We had ORR of 29% versus monotherapy to ventifusp of around 11%. We had PFS of 8.1% versus again, monotherapy, um, to vent if us, but around 3.4 and then a duration of therapy, which is sorry, duration of response of 24 months. So again, across all metrics, almost a doubling in some cases, almost tripling of benefit. And if you look at survival, The two-year overall survival of the combination was around 70% compared to 45% for ChemTrack alone. So despite the innovation that ChemTracks has brought to the market of doubling overall survival in five years, obviously there's room to improve. And we think the combination of ChemTracked plus Bernanfusp is that improvement. I mean, I thought the data was stunning. I mean, really, I was buried in your press release there on earnings and then presented at the medical conference. So I wanted to highlight that. Maybe one final question on the landscape for uveal melanoma. There is a competitor out there that is filing to the FDA soon with an oral pill. My view and our models, you know, don't reflect any increase in competition, given your medicine is in an HLA-positive population, and that's what ChemTrack targets, versus their medicine is HLA negative. There are some data in HLA positive, but my viewpoint and UBS sees that ChemTracks should be pretty insulated in terms of our revenues over the next couple of years, given that you guys are the standard of care in first line, it is HLa positive. So maybe just talk about your expectations on how a new competitor entering the market for the first time in five years could impact the base business? Yeah, so I think, first of all, from our perspective, it's great to see innovation in unmet need. And from, again, our perspective that unmet need is in HLA-negative patients. If you look at where ChemTrack, as you just alluded to, is a well-established standard of care, and we talked about the penetration rates already that we have, we're going to continue to focus on the value proposition that ChemTracks has brought. But earlier this year, we disclosed our five-year overall survival, and I mentioned there was a doubling of overall survival at five years. Another important aspect in that same data set is that almost half of those patients only received ChemTrack. So it allows us to reinforce that messaging of start with ChemTracks and continue to treat as patients continue to benefit. And that's been something that's very consistent. We've heard from investigators as well. And the last aspect I'll mention is safety, the safety profile that we have with ChemTrack. I talked a bit about the product profile that has allowed us to be successful in the community setting. And safety is certainly part of that because community physicians have to get comfortable with that safety profile. And what you see is a very consistent and manageable safety profile that really, you know, you may see some CRS in the first few doses, but that's on mechanism. And then it goes to very low single digits of AEs. And we do not see, and we have the five-year overall data to show it, we do not see any cumulative toxicities. So I think that's very different than what you will often see from a small molecule. Okay. That makes sense. I guess focusing now and shifting to metastatic melanoma, I would say that you have a very interesting catalyst that just recently got pushed, which is the Tebby AM study in second line metastatic melanoma, where there's maybe two new therapies that are, have various different uses to say the least, you know, and not, and you know are just recently come to market. You are going to have this phase three data. I think it is now being pushed to Q2 27 and from as early that was potentially going to come this year. So maybe you just talk to us about your confidence in this study in being positive and maybe what is the magnitude of benefit that you would want to see in that in order for this to be, you know, practice changing in HLA positive second line metastatic melanoma? Yeah, so several aspects that give us confidence in starting a registrational randomized phase three study in advanced cutaneous melanoma. The first is, one, it's a life cycle management play for Chemtrak, right? So we've already shown a demonstrated survival benefit in uveal melanoma. So then you might ask, well, what's the consistency between uveil and continuous? And there's a lot of overlapping biology between those two tumors. Namely, the GP100 target that Chemtruk focuses on is incredibly highly expressed in both tumors, 85% plus, right, in both tumor. So there's very good consistency there. And I think the third aspect I'll mention is if you look back at Uveal, it was a tumor that was historically immune insensitive, right? A cold tumor, if you will. And if you Look at, and so Chemtrak was the first really innovation in that space in like 40 years. And I Think if you looked at the patient population with which we're studying in advanced cutaneous, these are very refractory patients. They've had to progress on a PD-1 within six months. So in many respects, they reflect that aspect of being cold tumor-like where we've seen success with Chemtrak. So I think all those things, including combining it with one of the arms is Chemtrek plus pembrolizumab. So combining two active agents that we know are active in cutaneous, all those Things contribute to the confidence we have in Tevye. Okay, great. I guess one follow-up question on that would be, you're enrolling the study globally, of course, But most, you know, cutaneous melanoma studies enroll majority OUS. And there is maybe various treatment landscapes for the control arm. And the controlarm in this study is actually very unique. And a lot of doctors have actually, in KOLs that we've spoken to, have praised the control arm because it resembles what real life is, which is there's not that many options. So you can either be followed with no treatment, go to a clinical trial, or maybe you have retreatment of chemo. But maybe talk through what are the options that we can expect to see in this control arm and how, you know, given there are so many options one can get, how can we think about that median, you knows, OS benefit that we see in the control arm? Yeah. So if you look across this line of therapy, so a few things to point out. The trial design says that patients have to have failed ipinevo, so PD-1 plus CTLA-4. And they've also had to have failing a BRAF therapy if they were BRAF mutant eligible. So if we look at that patient population, there's been no therapy that's ever shown an overall survival benefit in a randomized study. So this is a very, obviously, high M at need, which is why, and there's no standard, and as such, there's no standard of care in these patients. So it's why we designed the study, Tebiam, how we did to allow for locally available therapy in that control arm. So then to your question of what do we expect to see? So if we look across the real world evidence in this space, despite there not being a standard of of care, what we intend to see is roughly, again, roughly, this is going off real-world evidence, we see about a third of some PD-1-based retreatment. Okay. Probably 20-25% BRAF retreatment and then the rest, unfortunately for patients, being chemo or palliative care, maybe a small number of clinical trials. Okay And then to your earlier question that we get relatively frequently because the trial is largely enrolled in Europe, which is consistent for any current melanoma trial study that's been conducted. Yeah. We're not going to see those newer therapies that you alluded to. Okay. Cause they're not approved there. Yeah, no, that makes sense. I guess on the, the most common thing is to retreat or chemo besides, you know, a clinical trial. When you think about retreatment, um, PD one, uh, like IO retreatment is what you were saying, maybe one-third of the patients get. So are they just being retreated maybe with Keytruda or Nuvilumab, or are patients also getting, you know, ipinivo as well? Is that also a possibility given the patient population had to have failed and been refractory already to ipin vivo to be included in this trial? And so I guess I'm wondering on that because, you know even if they had failed PD-1, they could still get retreated with it, but if they failed ipinevo can they also be retreated with it just given the nature of that there is limited options yeah they they can be a lot of a lot that will be dictated by what is approved and reimbursed in various countries right so i suspect there's going to be a fair amount of pd1 monotherapy yep there'll be some ipinebo probably retreatment yep um there'll also probably be some um all all those small numbers because, uh, in Europe, PD-1-like-3 is only approved in PD-2-negative. Right. So if you, if from our perspective, you kind of take all those and the best, the best publication we really have is on ipinevo retreatment. It was a retrospective study, albeit only 25 patients. Yeah. The retreatment on ipnevo when they were 100% PD-10-CTLA-4 treated previously. So it was truly a retreatment of the same regimen was around nine to 10 months. Okay. Um, but if you look across kind of all the, that blend and including everything else I mentioned, chemo, unfortunately, chemо is shown to only, it's not very effective. It's only shown to be about six months. Okay. So if you take a blend of all those segments that I mentioned earlier, we're expecting about 10 to 11 months in the control arm. And then your drug arm in the, uh, phase two that was done many years ago, um, you know, that's what I think around 16 to 18 months, depending on the different subgroups. And, you know, that was done, I think conducted maybe a couple of years ago, and it was not in combination with Keytruda, but in combination with, um, uh, the role map. So my question then, I Think Keytrude is obviously a stronger, um、 you know PD-1 regimen. Would you expect that maybe there is, you know, the drug arm or the combination arm in your study in TBIM could maybe do a little bit better, um, than you had originally seen just given the difference in that combination with Kajuda versus Deverell lab? Uh, maybe there's potential for that. I wouldn't say that's our base expectation. I think we feel strongly that if we recapitulate that roughly 60 patients that you're alluding to earlier in phase one, we'll feel confident in the outcome of the study. Okay, great. What do you think is clinically meaningful? I mean, some of the KOLs that we've talked to at ASCO say, you know, a Delta of, you Know, maybe two to three month difference on os is is as much as clinically meaningful you know that's as long as we you know has a ratio of 0.8 you know would be something that would change the practice just given that there is limited options um how are you guys thinking about what is a clinically meaningful result um for for the study yes so we haven't disclosed the details of the statistical analysis plan but what i'll anchor back to is there's been no therapy that's been able to show an overall survival benefit in this patient population so if we were able to show that statistically significant overall survival benefit, we feel good about our commercial aspects. Okay, great. So this data is going to come Q2. So are we thinking that that could maybe be early Q2, mid Q2? You know, late Q2 what are we thinking? Is this going to be a late breaker at ASCO next year? Should we book our hotels and flights already they get pretty expensive or how should we think about that we sure hope all that comes true yes yes feel free um no in all seriousness um you know it's an overall survival driven endpoint so we have to leave it leave ourselves wiggle room so i think it's best statistic to q2 at this point so we we did um some uh analysis recently and our take is on the margin having this pushed out from uh late this year into q2 next year is maybe a little bit positive because that could suggest that events are taking a little bit longer to accrue. And so that means that there is maybe, you know, patients are surviving longer, correct? Especially on the combination arm, which would be the most logical explanation given we have a pretty good understanding of how long patients last on the control arm. What do you guys make of that? You know, are we on the right track or should we rethink our analysis? Yeah. First and foremost, we can't see the data, right? I need to make that, obviously make that comment. It's, it's blinded. So for the, it'S, you know, for the integrity of the trial, we can see the data. That being said, let me give you a little more insight as to the, what I'll call shift in timing from, we were previously saying as early as the end of the year, really reflecting a couple of things. One, that's no for all survival driven endpoint. There's flexibility with that. We also hadn't completed enrollment yet. So we completed an enrollment last quarter And that gave us more specific insight into how those events were occurring from an independent stats group. So I wouldn't read too much into the shift in timing. I'd more reflect it as better data and, you know, pointing to Q2 versus as early as the end of the year. Okay. Got it. Maybe then shifting to the remaining oncology pipeline, we've just hit on basically the base business, the next near-term catalyst, which is Tebby AM. um you have a big large actually first line melanoma uh frame program that's ongoing i know this is a little bit more further out the data initially i think was a little bit confusing for investors in wall street maybe just thinking through um this is still enrolling now and it takes about three years to enroll and i believe this was started enrolling in 2024 is when i believe i was at asco and i remember uh bahija telling me that we just enrolled our first patient. So I would, I want to say that we could probably get to 2027. Can we expect enrollment to complete around then, or how should we think about that? And, you know, if you can guide to anything about the PRAME studies. Yeah, no, happy to. So let me, so the, the study is referred to as PRISM-MEL. So this is a frontline cutaneous melanoma, um, study with, um. Bernadifusp versus, plus, uh, nivolumab versus as a Novobab-based regimen. And so enrollment's been going very well. We are on track to complete enrollment in 2027, and it's always encouraging to see enrollment go very well, I think the other aspect I'll say is some of the confidence you're alluding to. What gave us the confidence to run the registrational trial? And I think it's a multitude of things. One is we generated and saw good activity in Bernadifest as a monotherapy. I think that's an important thing to mention. Yes, it was in a later line of cutaneous melanoma, but seeing that monotherapy data, and if you look at the disease control rate as a Monotherapy, it exceeded the combination of Nevo lag three, for example, where I think we're all curious as to kind of come to the conclusion that lag three didn't have any monotherapy activity, despite these, to my knowledge, they're not having published it. um so that gave us and and then that combined with the aspect that we know from our t-cell right um driven um platform yeah that moving into earlier lines you have healthier t-cel fitness okay um and so combining those two things combined with then the given the uh experimental arm with with bernetta fuss is plus nivolumab so you have two distinct mechanisms of action that you know from our base case or if you will have a at least a minimum of an added effect yep potentially even a synergistic effect so you take all those things combined and that that's sort of that was gives us the confidence uh in prismo um no that makes sense um i guess so it sounds like you guys are on track to enroll in or finish enrollment in 2027 um rough estimate and obviously i know you guys haven't guided to and would be premature to but maybe just thinking about how long in a first line, when you look at the Abdullak studies, how long does it take to a PFS endpoint in just looking at historical first line melanoma trials? Yes, correct. It is a primary endpoint is PFS. And somewhere between, right now we're saying somewhere between six and 10 months. So sometime in 2028. Okay. Got it. Okay, great. So that's another catalyst to look forward to. And to be honest, 2020, it's not that far away. Um, okay, great. Um, I did notice that in your recent update, um, on moving from oncology, moving on to, um uh, HIV actually, which I think is, you know, a very interesting space. Um maybe just thinking about, um you were supposed to have an update with the higher doses later this year, but that also got moved to next year. Talk through, uh, why that was pushed out, what you're waiting to see and what we're expecting to happen with that program? And maybe just refresh us on the data. It is quite an interesting program. And I think, you know, you guys don't, maybe it's a little bit under the radar given everyone's focus on oncology, but maybe just talk through that a bit. Yeah. So I think our efforts in both infectious disease and autoimmune speak to the modularity of the platform, right? So this is, this is allows us to change out various components of the bispecific to then address other T-cell-mediated diseases. And so one of the things we're looking for in infectious disease, this is a high bar. We're looking to achieve a functional cure. That is the intent around the HIV program. So we saw encouraging initially, which we disclosed at CROI in 2025. I had to get my years correct. Yeah, I think it was 2025. It was 2025, March 2025. I remember where I was exactly. Um, we, we had encouraging signs of antiviral activity, but we wanted to further optimize and further demonstrate even, you know, additional activity. So we continue to dose escalate. We did not hit any dose limiting toxicities. So we can need to take those, those doses higher. So what we've recently, um, been able to achieve is we've now taken, um. That platform up to 1200 micrograms. Um, it's actually higher than we had gone in any previous aspects of the platform and and continue to see good safety. So what we'll be looking to disclose next year at a medical conference that I can't name quite yet is to disclose that activity. Okay, great. So it will be at a mental conference, presumably one where HIV data is presented. There's two of them, so I'll look forward to a couple of them. But two big ones. But not many, yes. So I look forward for that data. It's interesting you brought in your INI portfolio, which I actually think is even more under the radar than HIV. And actually I was talking to a couple of investors and they brought it up a couple months ago. You have a PD-1 agonist that you guys are taking forward into the clinic, I think, this year. Walk us through that. I believe it is going with type 1 diabetes and then maybe potentially atopic dermatitis. But you haven't really talked much about that. So maybe, you know, in the last five minutes or so, talk about what your strategy is from Unicor. You know, INI is a pretty big space. multi-blockbuster and there's many different indications that you can go in, maybe talk through what is the strategy from Unicor from and the assets that you guys currently have in development? Yeah, I'm really excited that we've gotten this underway. So we dosed our first patient with type 1 diabetes last quarter. And this goes back to that modularity of the platform that I was referring to. So our strategy on the autoimmune side is to take what we've learned in oncology and apply it to immunology. And specifically, the aspect I mean from that is we are able to deliver very specifically to the tumor in onc biology. We've now been able to demonstrate that. We believe we can do the same thing in immunology and have a tissue-specific approach. So to talk about the type 1 diabetes program in a little more detail, The bispecific that we've designed for type 1 has two components. It's a pre-pro-insulin targeting. Pre-proinsulin is expressed explicitly in beta cells in the pancreas. So think of that as the targeting aspect of the bispespecific. The other side, as you alluded to, is a PD-1 agonist. We know type 1 diabetes is an almost purely T-cell-mediated and driven disease. So the intent is to stop the T cells by the PD-1 agonism, to stop the T-cells from attacking the beta cells and therefore preserving insulin production. So it's something we're incredibly excited about because I think, and if this is a proof of concept, if you will, for autoimmune and being tissue-specific, because if we're able to show this tissue- specific aspect of down-regulating the immune system, it opens up a plethora of other opportunities for us. um and what's so we're the single ascending dose is underway um another thing that that i like from the cfo perspective is this is a very capital efficient program meaning we will be able to get very we'll be ableto get data from the sad and the mad that gives us confidence in moving forward um it's assuming the data looks good and when i and to give you a little more sense of what i'm talking about there is single ascended dose will really be looking for pd1 we're looking we're We're looking for upper target engagement and therefore looking for soluble PD-1 and making sure there's an increase in solublePD-1. That gives us confidence in the target engagement. Assuming we see that, we'll move to the multiple ascending dose where we can look at C-peptide. C-PEPTIDE is an approvable endpoint as demonstrated by teplizumab. And so we'll be able to see C-PEPTIDE data in the multiple descending dose data because the phase one is being run in people with type 1 diabetes. Yeah. Yeah. And so that gives us, you know, that allows us for a very efficient manner to to see clinical activity in a short amount of time. Yeah. So, you Know, it's underway. OK. Maybe a little too early to comment on when we expect to have results. Yeah. Because we've only dosed the first patient so far. Yeah. But but stay tuned. We'll obviously update on timing as soon as we can. It was interesting when we had met in your offices in just here, actually the headquarters in England. um, a couple of years ago, I believe that you guys were talking about maybe getting initial data and then maybe partnering out this program. Um, is that still the case or would you guys develop this in house? If you did see good, see peptide data and good target engagement in the sad mad, would you, you know, move this forward? I mean, you Know, it's, it'S not like you need to go out and raise a lot of money to take this forward. You guys are pretty well, you know, um, capitalized, but you know how are you thinking about that? Yeah, we, we are well capitalized right with just over 900 million dollars of cash on the balance sheet but we we also want to be good stewards and efficient with that capital yeah um so if you look at where we're most established it's in oncology right we have a development and commercial footprint in oncogy so i think it's logical to say if we look at auto as you look autoimmune and infectious disease we'll look to take those two we'll likely to look at to take these two inflection points and then look for partners that have more established presence there okay so it's more of a timing thing like the the value inflection we think we can generate with efficient capital as i alluded to in those in those areas is is strong yeah and then from there we'll probably look for someone else to help maximize value in those programs okay have you started obviously with me with i and i way too early we're still not even you know uh kind of data but we've seen good data so far with hiv would you say that you've had conversations and you know you're just waiting on additional data to engage more with uh partners or how should we think about that. Yeah. It's fair to say from a business development perspective, you're always having those conversations, right? Um, cause you're Always looking for opportunities so that it's fair to see that's just a consistent thing we do as part of the business. Well, you know, there are two key HIV players and one of them is in this country. So, uh, just, you know, um, well, I think that's all the time we have for today. Thank you so much for taking this time to talk through this. I thought it was very insightful and, um. Thank you again. No, thank you again for having us. Appreciate it.
- Company
- IMMUNOCORE HOLDINGS PLC
- Keywords
- IMMUNOCORE HOLDINGS PLC